

## Results of Non-Renounceable Entitlement Offer

PainChek Ltd ACN 146 035 127 (ASX: PCK) (**PainChek** or **Company**) is pleased to advise that the 1 for 20 pro rata non renounceable entitlement offer at \$0.028 (**Entitlement Offer**) to raise approximately \$1.59 million (before costs) closed on 27 July 2022.

The Entitlement Offer gave eligible shareholders the opportunity to take up their pro rata entitlement by applying for new ordinary shares in PainChek (**New Shares**). Eligible shareholders were also able to apply for additional New Shares subject to a scale back. In respect of the applications received for additional New Shares, PainChek did not apply a scale back.

The Entitlement Offer opened on Monday 4 July 2022 and closed on Wednesday 27 July 2022.

Under the Entitlement Offer, PainChek received valid applications for 55,536,898 New Shares.

A summary of the Entitlement Offer results has been included below:

Total number of New Shares offered under the Entitlement Offer	56,632,143
New Shares applied for and accepted under the Entitlement Offer	55,536,898
Shortfall Shares	1,095,245

PainChek has mandated Canaccord Genuity (Australia) Limited, as Lead Manager, to place the shortfall shares. PainChek expects the placement of the shortfall shares to be completed by 2 August 2022.

The New Shares taken up under the Entitlement Offer are expected to be issued on Wednesday 3 August 2022 and expected to commence trading on Thursday 4 August 2022.

Authorised by:

The Board of Directors, PainChek Ltd

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere.

PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who have not yet learnt to speak. Both the adult and infants products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit [www.painchek.com](http://www.painchek.com)